Top 5 Biotech Stocks To Watch Right Now

Support for medical marijuana is at an all-time high in the U.S. The first marijuana plant-based prescription drug is on the verge of winning FDA approval for treating two rare forms of epilepsy. But could cannabis-based drugs target more common indications that affect millions of Americans? Maybe so.

A recent survey uncovered some intriguing news about how some individuals are using marijuana. These results could hint at the potential for biotechs to develop cannabinoids that can treat a problem that affects nearly 40 million Americans.

Image source: Getty Images.

Older adults and marijuana

It’s not just younger adults who support legalization of medical marijuana. In April, the AARP reported findings from a survey that found 80% of Americans between the ages of 50 and 80 either strongly or somewhat support the use of marijuana with a physician’s consent. Only 6% of these older individuals actually used marijuana themselves, though.

Top 5 Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

Top 5 Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

Top 5 Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Todd Campbell]

    PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluatingrisdiplam suggested it could mount a stiff challenge toBiogen’s (NASDAQ:BIIB)and Ionis Pharmaceuticals'(NASDAQ:IONS)Spinrazafor the treatment of spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis’ (NYSE:NVS), and that therapy could become available as soon as 2019.

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) shares jumped early on Friday after the firm, in conjunction with Eisai out of Japan, announced positive results from a midstage Alzheimers study. The topline results came from the Phase 2 study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease.

  • [By Brian Orelli]

    Likewise,Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS), which have the only SMA drug on the market, are feeling the heat from the promising data with shares down 5.6% and 7.3%, respectively.

  • [By Keith Speights]

    Ionis has solid revenue coming in the door thanks to Spinraza. Biogen (NASDAQ:BIIB) markets the spinal muscular atrophy (SMA) drug, but Ionis receives royalties on all sales. In Q1, those royalties totaled $41 million, up from $5 million in the prior-year period.

  • [By Garrett Baldwin]

    Markets are keeping a close eye on the 10-year bond, which is hovering near 3% – an important psychological level that is likely to influence future price movements. On Monday, Fox Business Network’s “Varney & Co.” asked Money Morning Chief Investment Strategist Keith Fitz-Gerald if investors should be worried. Here’s what Keith had to say about the 10-year Treasury yield… and how it will affect your stocks and bonds in the future.
    The price of Brent crude oil topped $75.00 and hit its highest level since November 2014. Oil traders were eyeing the ongoing efforts of OPEC and Russia to reduce excessive production around the globe, rising demand ahead of peak driving season, and the possibility that the Trump administration will slap Iran with a new round of sanctions.
    Three Stocks to Watch Today: KO, GOOGL, SLM
    Shares of The Coca-Cola Co.(NYSE: KO) added 1.2% after the firm easily beat earnings and revenue expectations. The firm cited strong demand for its new flavors of Diet Coke and its Coke Zero Sugar. Demand was so strong for the quarter that the firm reported organic sales growth of 5%. The company reported earnings per share of $0.47, topping estimates by a penny. Revenue of $7.6 billion easily beat Wall Street estimates.
    Shares of Alphabet Inc. (Nasdaq: GOOGL) seesawed in pre-market hours. The online search giant topped Wall Street earnings and revenue expectations after the bell Monday. However, shares were off 0.5% after executives announced that its business costs were on the rise. The firm’s real estate and computer purchases tripled in one year, to $7.3 billion. About one-third of that total came from its $2.4 billion purchase of the Chelsea Market building in New York City.
    Good news for SLM Corp.(NYSE: SLM) investors, but bad news for indebted college students and graduates. The firm – also known as Sallie Mae – topped Wall Street earnings expectations on Monday. The firm said that it increased its loan o

Top 5 Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Logan Wallace]

    AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Amgen (AMGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to release its most recent quarterly results on Thursday. The consensus forecast calls for $3.54 in EPS and $5.74 billion in revenue for the second quarter. Shares traded on Fridays close at $190.60. The consensus price target is $196.10, and the 52-week range is $163.31 to $201.23.

  • [By Todd Campbell]

    One of these two drugs is Amgen’s (NASDAQ:AMGN) Repatha, and the other is Praluent, which was co-developed by Sanofi SA (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN). Both drugs launched to billion-dollar blockbuster expectations, but because they’re complex biologics that are expensive to make, they cost about $14,000 per year. Their high cost, plus the fact that they’re injected rather than taken orally, may make them best suited for patients with stubbornly high cholesterol who are at the greatest risk of heart disease.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is waiting for the FDA to review its Biologics License Application (BLA) for Aimovig (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. The FDA has set a PDUFA date for May 17.

Leave a Reply

Your email address will not be published. Required fields are marked *